ITRM
vs
S&P 500
ITRM
S&P 500
Over the past 12 months, ITRM has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +19% growth.
Stocks Performance
ITRM vs S&P 500
Performance Gap
ITRM vs S&P 500
Performance By Year
ITRM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
